Table 3

 Median outcomes or frequencies (and interquartile ranges or percentages) at baseline and after 12 months’ follow up

CLVRELVRCELVR
Baseline (n = 76)12 months (n = 60)Baseline (n = 75)12 months (n = 64)Baseline (n = 75)12 months (n = 70)
NA, measured task performance and LVA use were not assessed at baseline.
†VCM1 scores are the average of 10 items, each scored from 0 to 5, with larger scores representing poorer vision related QoL.
‡SF-36 PCS and MCS component scores are normalised “T” scores—that is, a “normal” population is assumed to have a mean of 50 and SD of 10, with higher scores represent better QoL. Baseline data were incomplete for three patients allocated to CLVR, four allocated to ELVR, and two allocated to CELVR; 12 month follow up data were incomplete for onepatient allocated to ELVR.
§Minimum and maximum NAS scores for each dimension were 4–20 for locus of control, 9–45 for acceptance, 7–35 for attitude, and 8–40 for self efficacy, with larger scores representing “a more desirable state of affairs.”21 Baseline and 12 month follow up data for “acceptance” were incomplete for one patient allocated to ELVR; 12 month follow up NAS data for “attitude” were incomplete for one allocated to CLVR, and for “self efficacy” for one allocated to ELVR..
¶Task performance scores are frequencies (percentages); data at 12 months were missing for reading use by dates for one patient allocated to CLVR and one allocated to ELVR, and for reading medicine instructions for two allocated to CLVR,
††Baseline self rated restriction scores ranged from 0 to 1, with larger scores representing greater restriction. Data were incomplete for six patients allocated to CLVR, six allocated to ELVR, and nine allocated to CELVR; 12 month follow up data were incomplete for two patients allocated to CLVR and two allocated to ELVR.
‡‡Frequencies (percentages) are reported for these outcomes; all percentages are with respect to the total number of patients completing the trial in each arm. Baseline data were not collected, but LVA use was assessed at 4 months; however, some patients could not be contacted at 4 months to assess LVA use and denominators for CLVR, ELVR and CELVR were 57, 62, and 63.
VCM1†2.1 (1.7 to 2.8)2.4 (1.8 to 3.1)2.2 (1.5 to 2.7)2.5 (1.7 to 3.0)2.2 (1.4 to 2.7)2.3 (1.5 to 2.9)
SF-36: PCS‡36 (24 to 47)38 (24 to 44)33 (23 to 43)26 (14 to 40)31 (23 to 46)28 (17 to 41)
SF-36: MCS‡52 (44 to 60)52 (43 to 59)56 (51 to 59)53 (41 to 57)53 (47 to 59)53 (45 to 57)
NAS§
    Locus of control17 (15 to 19)18 (14 to 20)18 (16 to 19)18 (14 to 20)18 (16 to 20)18 (16 to 20)
    Acceptance35 (29 to 41)38 (27 to 41)36 (29 to 41)36 (29 to 42)37 (30 to 41)38 (29 to 42)
    Attitude19 (16 to 24)20 (15 to 23)20 (17 to 24)20 (17 to 24)20 (17 to 23)19 (17 to 25)
    Self efficacy28 (24 to 33)28 (24 to 33)29 (25 to 34)28 (23 to 33)28 (23 to 34)29 (24 to 34)
Measured task performance¶
    Read one or both use by datesNA39 (66.1%)NA39 (61.9%)NA54 (77.1%)
    Read drug nameNA32 (55.2%)NA30 (46.9%)NA43 (61.4%)
MLVQ
    Self rated restriction score††0.6 (0.3 to 0.7)0.6 (0.4 to 0.7)0.5 (0.3 to 0.7)0.6 (0.4 to 0.7)0.5 (0.2 to 0.6)0.4 (0.3 to 0.6)
    Using at least one LVA‡‡52 (91.2%)57 (95.0%)62 (100%)58 (90.6%)58 (92.1%)67 (95.7%)
    Using an LVA daily‡‡36 (63.2%)42 (70.0%)45 (72.6%)47 (73.4%)43 (68.3%)51 (72.9%)
    Using an LVA for ⩾5 minutes‡‡32 (56.1%)18 (30.0%)35 (56.5%)22 (34.4%)33 (52.4%)16 (22.9%)